Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 389479 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
Site LicenseAdd to Basket
EnterprisewideAdd to Basket
EnterprisewideAdd to Basket
Site LicenseAdd to Basket



Genomics and Proteomics Markets in Australia
Frost & Sullivan, June 2005


  Description  
  Table of Contents  
    
    
    
   
 Enquire before Buying  
 Send to a Friend  

Increasing Research Drives Genomics and Proteomics Market in Australia

Extensive research in genomics and proteomics is promising cures for previously untreatable diseases. With the Government assisting by providing additional tax concessions, the spending on research and development (R&D) is likely to increase by 66.0 percent in 2005. As a result, more than 300 biotechnology companies focusing on genomics and proteomics applications have set up operations in Australia to take advantage of this favorable environment. Drug discovery companies are also likely to have ample opportunities to slightly modify the lead compound in order to screen and exclude patients of a certain genotype who are more prone to developing certain side effects from clinical trials.

This Frost & Sullivan research service provides an overview of and an outlook for the Australian genomics and proteomics market. It segments the market into structural and functional genomics and structural and functional proteomics. It provides detailed revenue forecasts and market share analyses and is essential for both large and small market participants seeking to position themselves to earn maximum return on investments.

Research Companies Must Team-up with Venture Capitalists for Funds

Compared to Western countries, most of the Australian biotech companies are start-up undertakings that are in need of capital to support their research. However, venture capitalists (VCs) are hesitant to provide funds since these companies have few products in the final stages of drug discovery and have to wait for around ten years for their products to complete clinical trials before releasing them into the market.

The long gestation period and the low market awareness on the potential of biotech products have led to insufficient funding of the biotech ventures in Australia as investors perceive them as being too risky, points out the analyst of the research service. The Australian government and the top research companies should help VCs understand the commercial viability of their projects and the time required to market them. To do this, they need to work closer with the VCs and convince them of the effectiveness of their approaches in procuring positive results in the clinical trials.

Enterprises Must Supply Researchers with Superior Products at Lesser Costs

Researchers need to strike the right balance between choosing high-end products for their research and maintaining lower costs, emphasizes the analyst. New products such as those in structural proteomics can be expensive, and at times, complex and enterprises should convince researchers about their long-term benefits to drive their sales.

To encourage greater involvement in research from universities, biotech companies must educate the faculty on intellectual property (IP) issues, patent filing, and tracking of license agreements with third parties, and monitoring competitors' technologies. These universities need to allot more resources for developing enhanced commercialization processes and build managerial expertise in commercialization, deal structuring, and business development.





Customers who bought this item also bought

Proteomics - Global Strategic Business Report

Proteomics - Technologies, Markets and Companies

Post Genome Project Era Proteomics R&D Competition

Proteomics 2003

Technology Developments in Functional Proteomics (Technical Insights)

Chemical Genomics - Commercial Applications in Drug Discovery and Development

Has Genomics Failed to Deliver?

Novel Targets in Drug Discovery



Top of page


   All rights reserved. � Copyright 2008 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds